D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $5.00 price objective on the stock.

A number of other equities research analysts also recently commented on the stock. StockNews.com initiated coverage on shares of VolitionRx in a research report on Wednesday. They issued a “sell” rating for the company. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Stock Up 2.8 %

Shares of NYSE:VNRX opened at $0.58 on Wednesday. The company has a market cap of $53.93 million, a P/E ratio of -1.62 and a beta of 1.09. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.02. The company has a 50-day moving average price of $0.61 and a 200 day moving average price of $0.65.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VNRX. Geode Capital Management LLC increased its stake in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of VolitionRx during the 4th quarter worth approximately $29,000. Northern Trust Corp increased its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. increased its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of VolitionRx during the 4th quarter worth approximately $36,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.